Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth provides mid-year update
This estimate is pro forma as it excludes any potential restructuring charges resulting from the company’s ongoing review of business processes and systems. “Our expectations for 2006 reflect
This estimate is pro forma as it excludes any potential restructuring charges resulting from the company’s ongoing review of business processes and systems. “Our expectations for 2006 reflect
Glucotrol is indicated as an adjunct to diet for the control of hyperglycemia and the associated symptomatology in patients with non-insulin-dependent diabetes mellitus type-2 diabetes. Caraco Pharma will
Patients in the study, who took the drug as needed for up to seven nights per week, did not experience rebound insomnia after treatment with the drug was
Niaspan is the only FDA-approved once-daily prescription niacin formulation for the treatment of lipid disorders with the ability to elevate HDL, or ‘good,’ cholesterol by up to 26%.
Tigris acquired the rights to several small molecules, including GFB-204 and GGTI-2418. The company will pay development based milestones and royalties based on sales of the licensed products,
Oral mucositis results in inflammation and ulceration of the mouth and throat tissue lining and is the most common debilitating toxicity induced by chemotherapy and radiation therapy regimens.
Revenue rose to $793.4 million, up from $668.1 million in the second quarter a year ago. A large contributor to this was the company’s end-stage renal disease drug
Additionally, Olsen, who is the company’s current chief operating officer, will continue to serve in that capacity for both divisions while the board of directors engages in a
IQ announced that it has successfully completed PER.C6 clone generation for the production of its two fully human monoclonal antibodies, or mAbs, against the anthrax lethal toxin components
Professor David Garrod of Manchester’s Faculty of Life Sciences said the research, which was recently shortlisted for the Northwest Regional Development Agency’s Bionow project of the year, takes